New phase of development targets chronic pain and fibromyalgia

New treatment option now available across all UK nations

New first-line option for patients with pMMR and dMMR tumours in England

Celltrion’s biosimilar now fully aligned with ACTEMRA IV indications in US

New oral GLP-1 agonist aims to reshape chronic weight management

FDA validation and AI-designed therapies mark major shift in treatment strategy

New drug delivery system could transform treatment for chronic conditions

Dydrogesterone-only tablet returns after 17-year absence to support personalised care

US$30.9 million strategic equity deal strengthens oncology platform

MB310 study investigates safety and efficacy of precision microbiome therapy